Disease activity in patients with or without enthesitis at baseline
tofacitinib-treated, enthesitis
REMISSION, ENTHESITIS
Overall, regardless of baseline enthesitis location or severity, the proportion of tofacitinib-treated patients with enthesitis (LEI > 0 or SPARCC > 0) at baseline who achieved LDA or remission increased over time, though there were some fluctuations from months 1 to 6 (Supplementary Figs. 1, 2 [see Additional file Among patients with LEI > 0 at baseline, at month 3, MDA (≥ 5/7 criteria) rates were greater with tofacitinib vs placebo in patients with enthesitis at the lateral epicondyle humerus (5 mg BID only) and medial femoral condyle at baseline (both 5 and 10 mg BID; Supplementary Fig. 1a [see Additional file Among patients with SPARCC > 0 at baseline, at month 1, the proportion of patients who achieved MDA was greater with tofacitinib 10 mg BID vs placebo in patients with enthesitis at the lower sites only at baseline; at month 3, a greater proportion of patients with enthesitis at the upper and lower sites at baseline achieved MDA with tofacitinib 5 mg BID vs placebo (Supplementary Fig. 2a [see Additional file Across baseline enthesitis severity (LEI or SPARCC), some differences in MDA (≥ 5/7 criteria) or PASDAS/DAPSA LDA (> 1.9– < 3.2/ > 4– ≤ 14, respectively) rates between patients treated with tofacitinib vs placebo were observed at months 1 and 3 (Supplementary Fig. 1a–c, 2a–c [see Additional file Through month 3, remission rates were similar in patients with enthesitis at baseline treated with tofacitinib and placebo, except CPDAI remission (≤ 2) rates were higher at month 3 in patients with 2 affected LEI sites or ≥ 2– > 5 affected SPARCC sites at baseline who received tofacitinib 10 mg BID (Supplementary Figs. 1e–h, 2e–h [see Additional file The proportions of patients without enthesitis (LEI = 0 and SPARCC = 0) at baseline reporting LDA or remission were similar across treatments (Supplementary Fig. 3a–h [see Additional file 